While onsite at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, Dr. Andrew N. Wilner spoke with Dr. Paul W. O'Connor, about how sequencing the bevy of newly approved multiple sclerosis (MS) therapies, as well as those in the pipeline, might work.

At least Dr O'Connor has the integrity to say that there are two theories about the possible disease aetiology: ie inflammation causes degeneration or degenetation causes inflammation.

http://www.medscape.com/viewarticle/775959?src=nl_topic